Send Samples to:

Bioscience East, Suite 100
1999 N. Fitzsimons PKWY
Aurora, CO 80045
303-724-5663

 

 

 


Dr. Uwe Christians, Director

Dr. Uwe Christians created iC42 in 2001 and holds the position of Laboratory Director. Dr. Christians received his M.D. (with highest honors) and his Ph.D. in Experimental, Clinical Pharmacology and Toxicology from the Medizinische Hochschule Hannover in Hannover, Germany, where he is a board certified  pharmacologist, toxicologistand clinical pharmacologist. He is a Diplomat of the American Board of Clinical Pharmacology and a Master in Research Quality Assurance (British Association of Research Quality Assurance). Dr. Christians completed postdoctoral fellowships in Biopharmaceutical Sciences (Dr. L.Z. Benet) at the University of California, San Francisco, and in Cardiothoracic Surgery and Transplant Immunology (Dr. R.E. Morris) at the Stanford University Medical School. He joined the Department of Anesthesiology at the University of Colorado in Denver in 2001.

Dr. Jeffrey Galinkin, Co-Director

Dr. Jeffrey Galinkin joined iC42 in 2007 and holds the position of Co-Director.  Dr. Galinkin is a leader in pediatric research and he is dedicated to advancing pediatric pharmacology.  His goals are to develop less invasive pediatric diagnostic tools.  He has designed and conducted several clinical studies in all stages of clinical development and has served on multiple steering committees for multi-center trials and for multiple pharmaceutical company studies.  Locally, Dr. Galinkin is one of the Chairs of the IRB for the University of Colorado.  He also co-chairs the Scientific Advisory Committee for the University of Colorado’s Clinical Translational Science Institute (a NIH funded vehicle that provides infrastructure to clinical investigators throughout the University of Colorado).  In addition, Dr. Galinkin is the Chair of the Pharmacy and Therapeutics Committee at The Children’s Hospital.

Dedicated Service Team:

Dr. Jelena Klawitter

Dr. Klawitter joined iC42 in 2003 and holds the position of Assistant Professor. Dr. Klawitter is a chemist trained at the Universität Bremen where she also received a Ph.D. in analytical chemistry and biochemistry. She has extensively utilized a combination of proteomics and metabolomics strategies for the discovery of molecular mechanisms underlying drug toxicity, cancerogenicity, the anti-cancer effects of drugs and drug resistance, as well as for the discovery and development of biomarkers as clinical diagnostic tools for individualized and predictive medicine. Currently, one of Dr. Klawitter’s main research goals is to deconvolute the complex interactions of genetics, diseases, environmental effects and immunosuppressant drug treatment on the development of endothelial dysfunction and resulting organ failure. In addition, Dr. Klawitter is an expert in regulatory compliance and has received her Master of Research Quality Assurance (MRQA) by the British Association for Research Quality Assurance. She currently serves as our laboratory Quality Assurance Officer.

Dr. Jost Klawitter

Dr. Klawitter joined iC42 in 2003 and holds the position of Assistant Professor. He was awarded a Ph.D. in analytical chemistry and biochemistry by the Universität Bremen, Germany, (with highest honors) and received the 'Bruker Best Thesis award'. Dr. Klawitter now holds the rank of Assistant Professor at iC42 and his work is focused on biomarker discovery and validation. He uses mass spectrometry and NMR-based proteomics and metabolomics approaches for the profiling of small and large molecule biomarkers. His special interests are in the development of quantitative highly sensitive (sub pmol/L) targeted biomarker assays in body fluids such as human induced sputum, cerebro-spinal fluid, urine, tissue and plasma. For this he develops and automates assays that utilize innovative sample cleanup followed by multidimensional liquid chromatography mass spectrometry. Dr. Klawitter has planned and performed clinical and analytical studies in collaboration with pharmaceutical industries for several years and has functioned as Chief Technology Officer for Eurofins Medinet Denver from 2007-2009. He is an expert in regulatory compliance and received a Master of Research Quality Assurance (MRQA) by the British Association for Research Quality Assurance in 2007.

Dr. Touraj Shokati

Dr. Shokati joined iC42 in 2005 and holds the position of Senior Research Instructor. He received his Ph.D. in analytical chemistry and biochemistry from the Universität Bremen in Germany and is committed to advancing Metabolomic research to advance individualized medicine. At iC42, Dr. Shokati’s focus is on mass spectrometry and 1H-NMR-based metabolomics, drug metabolism and the development and validation of quantitative and toxicology screening assays. He also carries out organic synthesis of natural compounds and drug derivatives.

Keith Hoffman, BS

Mr. Hoffman joined iC42 in 2008 and holds the position of Lab Manager. He addresses challenging questions in the Pharmaceutical Industry by utilizing his experience in quantitative Bioanalytical Chemistry including advanced method development using LC/MS/MS in a GLP or Non-GLP environment. Mr. Hoffman has over 20 years of Pharmaceutical Industry experience in drug discovery and development, specifically in pharmacokinetics and drug metabolism. Here at iC42, he manages daily laboratory operations for over 20 scientists and for more than 15 mass spectrometers. His achievements include developing DMPK and Metabolite ID methods in vitro and in vivo methods for clinical compounds. He also has vast experience with clinical immunosuppressant assays for patients.

Björn Schniedewind

Mr. Schniedewind joined iC42 in 2006 and holds the position of Professional Research Assistant. He graduated as a chemical laboratory assistant in 2002 at the Universität Bremen, Germany. He now conducts therapeutic drug monitoring for iC42 and also focuses on the analysis of immunosuppressant drugs for clinical studies. Mr. Schniedewind has engaged in the bioanalytics of many clinical studies that have successfully been reported to regulatory agencies. Additional technologies that Mr. Schniedewind’s work includes, but is not limited to, are mass spectrometry-based assays, enzyme kinetic studies, preparative isolation of pure metabolites using HPLC and structural identification using ion trap and high-resolution mass spectrometry in combination with analysis of fragmentation patterns.

Jeff Consoer, MS

Mr. Consoer joined iC42 in 2004 and holds the position of Statistics Programmer and Database Manager. Jeff has over 25 years of experience in providing statistical programming for numerous industries that is focused largely on health research and regulated pharmaceutical clinical trials. In addition, he has experience developing and supporting clinical data systems and managing clinical data in active studies. This includes knowledge and experience with both FDA requirements and standards established by the International Clinical Data Interchange Standards Consortium (CDISC). Mr. Consoer also has a broad range of experience in supporting information technology, networking, and distributed computing. This includes work on development, implementation and management of enterprise and mission critical information systems, management of technical support personnel, and hands-on experience providing end user technical support.

Dr. Emily Kewley

Dr. Kewley joined iC42 in April 2011 as a Research Instructor/ Project Manager. Dr. Kewley obtained her Ph.D. in molecular physiology studying vascular disease and ischemia at the University of Birmingham, UK. She then did a 2 year postdoctoral fellowship at the University of Colorado at Denver, studying the molecular basis of acute lung injury. Currently, Dr. Kewley is involved in study planning, coordination and management, client communication including website and social media, generation of study documents, procedures and documentation, data management, data analysis and reporting. She also works in the lab setting including using analytics (LC/mass spectrometry, nuclear magnetic resonance spectroscopy), proteomics (2-D gels, mass spectrometry, database searches and data analysis), structure analysis of unknown compounds using NMR spectroscopy and HPLC-MS/MS and is currently being trained as a Quality Assurance officer.

Baharak Davari

Mrs Davari joined iC42 in 2010 and holds the position of Professional Research Assistant. She graduated as a Biologist from Azad University of Iran (Tehran). She has nearly accomplished her master’s degree in Biochemistry. Currently, she is contributing to drug metabolism research efforts focusing on the analysis of immunosuppressant drugs for clinical studies, including measuring 25-hydroxy Vitamin D2 and 25-hydroxy Vitamin D3 for clinical studies. Mrs Davari is also using mass spectrometry-based assays, enzyme kinetic studies, carrying out preparative isolation of pure metabolites using HPLC and doing structural identification using ion trap and high-resolution mass spectrometry, in combination with analysis of fragmentation pattern.